全支付方费率设定系统控制下肢血运重建手术的费用但未消除种族差异
该研究利用马里兰州2009至2015年数据库,分析腹股沟下开放旁路和血管内修复患者的费用差异。结果显示全支付方费率设定系统实施后费用增长趋于平稳,但非白人和医疗补助患者费用仍显著更高,非裔患者ICU入住和延长住院风险更高。
要点
- 全支付方费率设定系统实施后下肢血运重建费用增长趋于平稳。
- 开放手术中非裔患者费用较白人高6092美元,其他非白种人高3324美元。
- 非裔患者开放手术后ICU入住风险调整比值比为1.65。
核心结论
- 全支付方费率设定系统遏制了下肢血运重建费用的上涨,但非裔和医疗补助人群的费用仍不成比例地更高。
- 非裔患者下肢血运重建费用更高,可能由延长住院和ICU入住驱动。
研究设计与样本
- 利用国际疾病分类第九版编码从马里兰健康服务成本审查委员会数据库(2009-2015年)识别接受腹股沟下开放旁路和血管内修复的患者。
- 采用多变量广义线性模型回归分析报告调整患者人口学、合并症和保险状态后的费用差异,并用逻辑回归评估ICU入住、30天再入院、延长住院和院内死亡等质量指标。
主要发现
- 开放手术中,非裔患者费用较白人高6092美元(95%CI 4682-7501),其他非白种人高3324美元(95%CI 437-6212),均P≤0.024。
- 开放手术中,糖尿病患者费用增加2058美元(95%CI 837-3279,P<0.001),医疗补助患者较医疗保险患者费用增加4325美元(95%CI 1441-7209)。
- 开放手术中,严重肢体缺血与风险调整费用增加5254美元(95%CI 4014-6495)相关。
- 开放手术中,非裔患者ICU入住风险调整比值比为1.65(95%CI 1.46-1.86,P<0.001),延长住院风险调整比值比为1.56(95%CI 1.37-1.79,P<0.001)。
- 血管内修复中,非裔患者费用较白人高2642美元(95%CI 1574-3711),其他非白种人高4124美元(95%CI 2091-6157),均P<0.001;非裔患者再入院风险调整比值比为1.16(95%CI 1.03-1.29),延长住院风险调整比值比为1.34(95%CI 1.21-1.49),均P<0.010。
临床怎么用
- 作者认为可努力评估 contributing 社会经济因素、投资于与高费用相关的合并症的一级预防,并在马里兰州具有成本节约潜力的支付系统中识别克服现有种族差异的机制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with peripheral arterial disease often have high comorbidity burden that may complicate post-interventional course and drive increased health-care expenditures. Racial disparity had been observed in lower extremity revascularization (LER) patterns and outcomes. In 2014, Maryland adopted an all-payer rate-setting system to limit the rising hospitalization costs. This resulted in an aggregate payment system in which hospital compensation takes place as an overall per capita expenditure for hospital services. We sought to examine racial differences and other patient-level factors that might lead to discrepancies in LER hospital costs in the State of Maryland. METHODS: We used International Classification of Diseases, Ninth Revision codes to identify patients who underwent infrainguinal open bypass (open) and endovascular repair (endo) in the Maryland Health Services Cost Review Commission database (2009-2015). Multivariable generalized linear model regression analysis was conducted to report cost differences adjusting for patient-specific demographics, comorbidities, and insurance status. Logistic regression analysis was used to assess quality metrics: intensive care unit (ICU) admission, 30-day readmission, protracted length of stay (pLOS) (endo: pLOS >9, open: pLOS > 10 days) and in-hospital mortality. RESULTS: Among patients undergoing open, costs were higher for nonwhite patients (African-American [AA]: $6,092 [4,682-7,501], other: $3,324 [437-6,212]; both P ≤ 0.024), diabetics ($2,058 [837-3,279]; P < 0.001), and patients with Medicaid had an increased cost over Medicare patients by $4,325 (1,441-7,209). Critical limb ischemia (CLI) was associated with $5,254 (4,014-6,495) risk-adjusted cost increment. In addition, AA patients demonstrated higher risk-adjusted odds of ICU admission (adjusted odds ratio [aOR] [95% confidence interval {CI}]:1.65 [1.46-1.86]; P < 0.001) and pLOS (aOR [95% CI]: 1.56 [1.37-1.79]; P < 0.001) than their white counterparts. For patients undergoing endo, costs were higher for nonwhite patients (AA: $2,642 [1,574-3,711], other: $4,124 [2,091-6,157]; both P < 0.001). Patients with CLI and heart failure had increased costs after endo. AA patients were more likely to be readmitted or stayed longer after endo (1.16 [1.03-1.29], 1.34 [1.21-1.49]; both P < 0.010, respectively). The overall cost trend was rapidly increasing before all-payer rate policy implementation but it dramatically plateaued after 2014. CONCLUSIONS: This study showed that the all-payer rate-setting system has curbed the LER rising costs, but these costs remained disproportionally higher for disadvantaged populations such as AA and Medicaid communities. This underpins the existing racial disparity in LER. AA patients had higher LER costs, most likely driven by extended hospitalization and ICU admission. Efforts could be directed to evaluate the contributing socioeconomic factors, invest in primary prevention of comorbid conditions that had shown to be associated with prohibitive costs, and identify mechanisms to overcome the existing racial disparity in LER within the promising cost-saving payment system at the State of Maryland.
引用
- Nejim B, Beaulieu RJ, Alshaikh H, et al. A Unique All-Payer Rate-Setting System Controls the Cost but Not the Racial Disparity in Lower Extremity Revascularization Procedures. Ann Vasc Surg. 2018. PMID: 29783031. doi:10.1016/j.avsg.2018.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。